Welcome to our dedicated page for TAKEDA PHARMACEUTICAL CO SEC filings (Ticker: TAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TAKEDA PHARMACEUTICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TAKEDA PHARMACEUTICAL CO's regulatory disclosures and financial reporting.
Takeda Pharmaceutical Company Limited shareholder Elaine Shannon filed a notice of proposed sale of Takeda American Depositary Shares (ADSs). The filing lists up to 20,363 ADSs to be sold through Interactive Brokers LLC, with an aggregate market value of $355,334.35, and an anticipated sale date of August 11, 2026 on the NYSE. The ADSs derive from Restricted Stock Unit Awards – Vested granted as compensation in 2023 and 2024, and the filing notes a prior sale of 4,319 ADSs for $72,351.26 on July 13, 2026.
Nicola Greenway, affiliated with Takeda Pharmaceutical Company Limited, has filed to sell up to 34,603 American Depositary Shares (ADSs) of Takeda through Interactive Brokers LLC on or after August 7, 2026, with an indicated aggregate market value of $578,562.16. The ADSs were acquired primarily via vested Restricted Stock Unit Awards and participation in an Employee Stock Purchase Plan. During the past three months, Greenway has already sold 7,348 ADSs for proceeds of $123,072.06.
Takeda Pharmaceutical Company received U.S. FDA approval for ORZEYFUL (oveporexton), an oral orexin receptor 2 (OX2R) agonist indicated for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adults. As a first-in-class orexin treatment, it is described as the only medicine in the U.S. that treats the underlying disease holistically rather than individual symptoms. Approval is supported by the global Phase 3 FirstLight and RadiantLight studies, which showed statistically significant improvements across excessive daytime sleepiness, cataplexy and health-related quality of life, with oveporexton generally well tolerated.
NT1, a rare chronic neurological disease driven by orexin loss, affects an estimated 120,000 people in the U.S. In pooled Phase 3 data, insomnia occurred in 60% of patients on ORZEYFUL 2 mg twice daily versus 1% on placebo, and urinary frequency in 58% versus 5%. Asymptomatic creatine phosphokinase elevations >5x ULN were seen in 11% of ORZEYFUL-treated patients and 5% on placebo. ORZEYFUL has abuse potential and awaits Drug Enforcement Administration controlled-substance scheduling, expected within 90 days, after which it will be available via specialty pharmacy. The company states the FDA approval is not expected to have a significant impact on the consolidated financial forecast for the fiscal year ending March 31, 2027.
Takeda Pharmaceutical Company Limited reported consolidated IFRS results for the three months ended June 30, 2026. Revenue was 1,219.9 billion JPY, up 10.2% year-on-year, largely reflecting Japanese yen depreciation, with growth in GI and Oncology driven by key brands such as ENTYVIO and ADCETRIS. Operating profit rose to 201.4 billion JPY, up 9.1%, while net profit attributable to owners declined to 113.2 billion JPY, down 8.9%, and basic EPS was 71.65 JPY.
Core Revenue matched reported revenue at 1,219.9 billion JPY, with Core Operating Profit increasing to 358.9 billion JPY, up 11.5% on an actual-rate basis, and Core EPS edging up to 154 JPY. Net cash from operating activities fell to 127.6 billion JPY and Adjusted Free Cash Flow to 68.6 billion JPY, while the ratio of equity attributable to owners to total assets was 48.3% and Adjusted Net Debt/Adjusted EBITDA was 2.7x.
For the fiscal year ending March 31, 2027, the company forecasts revenue of 4,640.0 billion JPY, operating profit of 420.0 billion JPY and net profit attributable to owners of 166.0 billion JPY, with Core EPS of 472 JPY. Management guidance at constant exchange rates calls for a low-single-digit percentage decline in Core Revenue, a 5% to 8% decline in Core Operating Profit and a mid-teens percentage decline in Core EPS.
Takeda Pharmaceutical Company Limited filed a notice for the proposed sale of 24,887 American Depositary Shares (ADSs) through Interactive Brokers LLC on or about July 13, 2026 on the NYSE, with an aggregate market value of $416,850.49. The filing lists 143,310,556 ADSs outstanding as context. It also notes prior transactions over the past three months, including 56,486 ADSs related to Restricted Stock Unit Awards – Vested dated July 1, 2026 and categorized as compensation.
Takeda Pharmaceutical Company Limited has a holder planning a resale of its American Depositary Shares under Rule 144. The plan covers 51,579 ADSs to be sold through Interactive Brokers LLC on the NYSE, with an aggregate market value of $863,947.36. The securities relate to Restricted Stock Unit Awards – Vested, with 109,202 ADSs acquired as compensation on July 1, 2026, of which a portion is covered by this planned sale as of a proposed sale date of July 13, 2026.
Takeda Pharmaceutical Company Limited filed to permit the sale of 33,696 American Depositary Shares (ADSs) through Interactive Brokers LLC on 07/13/2026 on the NYSE. The proposed sale has an aggregate market value of $564,406.02.
Over the prior three months, 126,794 ADSs were sold on 07/01/2026, arising from Restricted Stock Unit Awards – Vested granted as compensation.
Takeda Pharmaceutical Company Limited has a shareholder planning to sell American Depositary Shares (ADSs) through Interactive Brokers LLC on the NYSE. The proposed sale covers 33,454 ADSs with an approximate aggregate value of $560,351.40 as of a planned sale date of July 13, 2026. In the prior three months, 65,890 ADSs were involved in transactions tied to Restricted Stock Unit Awards – Vested dated July 1, 2026, categorized as compensation-related activity.
An affiliate of Takeda Pharmaceutical Company Limited plans to sell up to 27,197 American Depositary Shares (ADSs) of Takeda through Interactive Brokers LLC on or after July 13, 2026 under Rule 144. These ADSs come from 61,830 ADSs acquired on July 1, 2026 via vested Restricted Stock Unit Awards granted as compensation. The ADSs are listed on the NYSE, with 143,310,556 ADSs outstanding.
Takeda Pharmaceutical Company Limited is registering the potential sale of 19,754 American Depositary Shares (ADSs), corresponding to vested Restricted Stock Unit Awards. The ADSs were acquired as compensation on July 1, 2026 and are proposed to be sold through Interactive Brokers LLC on the NYSE. The filing indicates an aggregate market value of approximately $123,072.06 for the ADSs covered.